Submenu
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
ABOUT US
OUR SCIENCE
CLINICAL TRIALS
NEWS
CAREERS
FOR PATIENTS
PRESS RELEASES
NEWS COVERAGE
EVENTS
News

PRESS RELEASES

Featured press release
Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy
January 31, 2023

Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy

Glioblastoma
Melanoma
Bladder Cancer
Head and Neck Cancer
Istari
Filter by
2021
2020
Before 2020
Recent press releases
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy for PVSRIPO in Patients with Advanced Solid Tumors
April 19, 2021

Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy for PVSRIPO in Patients with Advanced Solid Tumors

During 2021

Bladder Cancer

Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting Reflect Continued Progress in the Clinical Development of PVSRIPO
April 6, 2021

Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting Reflect Continued Progress in the Clinical Development of PVSRIPO

During 2021

Glioblastoma, Bladder Cancer

Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO With and Without Immune Checkpoint Blockade in Advanced PD-1/L1 Refractory Melanoma
March 31, 2021

Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO With and Without Immune Checkpoint Blockade in Advanced PD-1/L1 Refractory Melanoma

During 2021

Melanoma

Published Research in Nature Communications: PVSRIPO Leads to Robust, Functional T Cells — Critical for Antitumor Immunity
March 25, 2021

Published Research in Nature Communications: PVSRIPO Leads to Robust, Functional T Cells — Critical for Antitumor Immunity

During 2021

Istari inc

Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma
January 10, 2021

Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma

During 2021

Melanoma

Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma
November 30, 2020

Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma

During 2020

Glioblastoma

Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
November 16, 2020

Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

During 2020

Melanoma

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
November 9, 2020

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

During 2020

Melanoma

Istari Oncology Announces NEJM Publication of Phase 1 Trial Results in Patients with Recurrent Glioblastoma Treated with PVSRIPO
June 26, 2018

Istari Oncology Announces NEJM Publication of Phase 1 Trial Results in Patients with Recurrent Glioblastoma Treated with PVSRIPO

Before 2020

Glioblastoma